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Abstract
Many genome-wide association studies (GWAS) have identified signals located in non-coding 
regions, and an increasing number of functional genomics annotations of regulatory elements and 
assays of regulatory activity have been used to investigate mechanisms. Genome-wide datasets 
that characterize chromatin structure help detect potential regulatory elements. Assays to 
experimentally assess candidate variants include transcriptional reporter assays, and recently, 
massively parallel reporter assays (MPRAs). Additionally, the effect of candidate regulatory 
elements and variants on gene expression and function can be evaluated using genomic editing 
with the CRISPR-Cas9 technology. We highlight some recent studies that employed these 
strategies to identify variant effects and elucidate molecular and/or biological mechanisms at 
GWAS loci for lipid traits and coronary artery disease.
Introduction
Human genome-wide association studies (GWAS) have identified hundreds of DNA variants 
associated with blood lipid levels and coronary artery disease. Blood lipid levels are a risk 
factor for cardiovascular disease, including increased low-density lipoprotein cholesterol 
(LDL-C), and increased triglycerides [1,2]. GWAS have been very successful at identifying 
genetic variants associated with these complex metabolic diseases [3,4] however, 
characterizing the molecular mechanisms responsible for these associations has been 
challenging.
Most variants identified by GWAS are located within non-coding regions of the genome [5], 
suggesting that these variants do not alter the structure or function of the encoded proteins. 
Variants located within regulatory elements, such as enhancer or silencer regions, may act to 
enhance or reduce gene expression. These regulatory regions may affect multiple genes and 
may regulate genes located hundreds of kilobases away [6,7]. Current challenges are to 
identify which GWAS variants have regulatory functions and to characterize the molecular 
mechanisms by which allelic differences affect gene activity and disease risk. Recently, 
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identification of regulatory elements and variants has been facilitated by technological 
development of genome-wide functional assays.
Experimental assays are necessary to determine which of the variants located in regulatory 
regions have allelic effects on regulatory activity. For example, transcriptional reporter 
assays are used to identify variants that alter promoter or enhancer/silencer activity, and 
recently, high-throughput approaches have been used to test dozens to thousands of 
candidate variants in a massively parallel fashion. Notably, GWAS studies identify lead 
variants that are most strongly associated with a trait or disease; however, these lead variants 
are not necessarily the functional regulatory variants due to sampling variation, technical, or 
stochastic reasons. Variants that are strongly linked, or inherited together (in strong linkage 
disequilibrium) with the lead variants may have regulatory effects, which highlights the need 
to test a number of variants in experimental assays. Reporter assays are often performed by 
cloning variant-containing regions into vectors containing a reporter gene and transfecting 
biologically-relevant cell types including induced pluripotent stem cells (iPSCs) that can be 
differentiated into several target cell types [8]. Another recent strategy for experimental 
evaluation of regulatory elements and variants uses CRISPR-Cas9-mediated genome editing. 
Cells or organisms can be edited to delete or alter the effect of a regulatory element or to 
create specific allelic substitutions.
Functional genomics regulatory annotation data can be used to help guide the selection of 
candidate regulatory elements and variants for experimental testing. These data are 
generated through the use of high-throughput methods, including open chromatin, chromatin 
conformation, and chromatin immunoprecipitation assays followed by high-throughput 
sequencing. These assays can be helpful at detecting candidate regulatory elements, 
including enhancer or silencer regions, which may ultimately aid in elucidating the 
mechanisms underlying the relationships between the GWAS variants and trait [9–11]. In 
this review, we discuss some recent approaches used to identify functional variants and 
mechanisms at lipid or coronary artery disease GWAS loci.
High-throughput functional genomics assays
High-throughput functional genomics assays of chromatin structure identify genomic 
regions characteristic of regulatory elements. Several consortia, including the Encyclopedia 
of DNA elements (ENCODE) consortium, the National Institutes of Health (NIH) Roadmap 
Epigenomics Mapping Consortium, and others in the International Human Epigenome 
Consortium [9,10,12] have generated genome-wide maps in hundreds of cell types and 
tissues. Maps of open, or accessible, chromatin denote DNA regions devoid of histones and 
more accessible to transcription factors, as detected by DNase hypersensitivity (DNase HS) 
[13] formaldehyde-assisted isolation of regulatory elements (FAIRE) [14] or assays for 
transposase-accessible chromatin (ATAC)-sequencing [15,16] (Table 1). Maps of histone 
modifications, detected through chromatin immunoprecipitation (ChIP)-sequencing [17,18]), 
can be integrated to predict chromatin state, including promoter, enhancer, and silencer 
regions [19], and regions bound by transcription factors can be further annotated with 
sequence binding motifs and to detect transcription factor footprints [17,20]. Maps of 
chromatin interactions, higher-order chromatin structure, topologically associated domains 
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(TADs), and frequently interacting regions (FIREs) are based on chromosome conformation 
capture methods, including Hi-C and chromatin interaction analysis by paired-end tag 
sequencing (ChIA-PET) [21–23].
Integrating these data and maps from trait-relevant cell types can be used to guide the 
identification of trait-associated variants located in regulatory regions. Data sets of 
chromatin accessibility and histone marks have differing signal strength compared to 
background and may be influenced by cellular environment, so multiple lines of evidence 
(i.e. peaks) can provide greater evidence of a regulatory element. Specific histone marks 
tend to be observed at different types of elements, such as H3K27ac marks at active 
enhancers. However, neither individual marks nor the absence of regulatory evidence from 
an assay is definitive, and mere presence of a variant in a region of histone marks does not 
indicate that the variant alleles alter regulatory activity [24]. While evidence of chromatin 
interactions between variant positions and a transcription start site supports the potential for 
a regulatory effect of variants on a gene, the interaction alone is not definitive, and absence 
of interactions may be due to assay resolution or cellular environment. Therefore, combining 
one or more pieces of evidence from high-throughput regulatory assay data with other 
functional genomics experiments, such as reporter assays and genomic editing, enhances the 
likelihood of identifying candidate regulatory variants.
Allelic differences in transcriptional activity
A common approach to examine variants for effects on transcriptional activity is a reporter 
assay. DNA segments of tens to thousands of base pairs containing individual allele(s) of a 
variant or haplotype are cloned into a vector containing a reporter gene, such as luciferase, 
whose activity is easily measured, and transfected into cells expected to express relevant 
transcription factors. The relative luciferase activity is compared between alleles and to a 
control lacking the inserted DNA segment (Figure 1).
Recently, individual or multiple regulatory variants have been shown to influence allelic 
differences in transcriptional activity at GWAS loci for lipid traits or coronary artery disease. 
At an association signal for triglycerides near TMEM241, the rs17259126-A allele showed 
higher transcriptional activity than the rs17259126-G allele and also stronger HNF4A 
protein binding [25]. The authors proposed that the rs17259126-G allele is associated with 
lower TMEM241 expression, leading to higher triglyceride levels. At an association signal 
for high density lipoprotein cholesterol (HDL-C) near ANGPTL8, the rs12463177-C allele 
was associated with lower ANGPTL8 expression, showed lower transcriptional activity in 
reporter assays, and decreased protein binding in electrophoretic mobility shift assays 
(EMSAs) [26]. At an association signal for coronary artery disease near GUCY1A3, the 
rs7692387-A allele showed higher transcriptional activity than the rs7692387-G coronary 
artery disease risk allele. Individuals homozygous for the risk allele showed lower 
expression of GUCY1A3 (encoding [alpha]1 subunit of soluble guanylyl cyclase (sGC)) in 
whole blood. In addition, human platelet-rich plasma samples homozygous for the risk allele 
showed a reduced effect on inhibition of both sGC stimulation and induced platelet 
aggregation [27]. Finally, at an association signal for coronary artery disease near PPAP2B 
(also known as PLPP3, encoding LPP3 protein), stimulating primary human macrophages 
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with oxidized LDL led to more strongly increased transcriptional enhancer activity for the 
rs72664324-A allele compared to the rs72664324-G allele [28]. In addition, the rs72664324-
G risk allele was associated with lower PPA2B expression (induced by oxidized LDL) in 
primary human macrophages. The authors hypothesized that lower expression results in 
reduced enzymatic function, which affects pro-inflammatory signaling in atherosclerotic 
plaques. For all of these examples, one or more chromatin annotations were used to select 
variants to test for regulatory activity, and further studies of regulatory and biological 
mechanisms would increase the rigor of the conclusions.
Transcriptional activity assays have also shown that more than one variant on the same 
haplotype can have allelic effects. At an HDL-C association signal near GALNT2, candidate 
variants were tested for allelic or haplotype differences in transcriptional activity regardless 
of chromatin annotation [24]. Two variants, rs2281721 and rs4846913, that are in strong 
linkage disequilibrium with each other (r2=0.96) and located ∼2 kb apart, showed strong 
allelic differences in transcriptional enhancer activity that matched the direction of variant 
association with GALNT2 expression level in adipose and liver. The alleles associated with 
increased HDL-C levels were associated with increased GALNT2 expression level and 
increased transcriptional enhancer activity. These data are consistent with subsequent 
evidence in rodents, non-human primates and humans that loss of the glycoprotein 
modifications by GALNT2 on target proteins, including phospholipid transfer protein 
(PLTP), led to lower HDL-C levels [29]. These variants also showed differential binding to 
USF1 and CEBPB in EMSA and ChIP assays. These findings suggest that multiple variants 
may act together to contribute to transcriptional activity and the underlying molecular 
mechanism(s) at GWAS lipid loci.
Overall, transcriptional reporter assays are valuable to demonstrate that specific nucleotides 
can increase or decrease transcriptional activity, especially in enhancer regions. At some 
loci, including a stimulus can better capture allelic differences in regulatory activity and 
simulate how variants act in vivo. Transcriptional reporter assays for individual variants are 
feasible to implement in a research laboratory with moderate cost and minimal 
computational requirements. However, these assays examine DNA segments and variants 
subcloned into vectors, removing the region from its natural chromatin conformation and 
cellular context. In addition, these assays are low-throughput, allowing only a few DNA 
variants to be analyzed concurrently.
High-throughput screens for regulatory variants
The advent of high-throughput, massively parallel reporter assays (MPRAs) have enabled 
multiple variants and regulatory regions to be analyzed more rapidly and efficiently. These 
methods typically use a barcode or tag at the end of the reporter gene to facilitate high-
throughput sequencing and quantification of expressed sequence reads [30–33]. In another 
design, expression level of the regulatory region itself is assayed [34,35].
Recent studies have applied MPRA methods to lipid and coronary artery disease loci. 
Tewhey and colleagues used MPRA in lymphoblastoid cell lines to test variants associated 
with gene expression levels. Tested variants included 9,664 variants at 163 GWAS loci for a 
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wide range of traits; of these, 248 variants (2.6%) exhibited allelic differences. For example, 
at an association signal for coronary artery disease near UBE2Z, a screen of 105 variants in 
MPRAs detected eight variants that showed allelic differences, one of which, rs4378658, is 
also located in an ENCODE-annotated regulatory region [36]. This study also reported 
allelic differences in MPRA for rs342468 near AFF1 at a triglycerides locus. In another 
study, Pashos and colleagues used MPRAs in NIH 3T3 fibroblasts to screen candidate 
functional variants at lipid GWAS loci that were also associated with gene expression levels 
in hepatocyte-like cells. They screened 525 variants across three loci and reported the single 
variant at each locus that showed the strongest evidence of allelic differences [37]. Among 
the variants at the three loci, rs10872142 also overlapped regulatory chromatin annotations 
in human liver and adipose cells (Figure 2). rs10872142 is in strong linkage disequilibrium 
(r2=0.97, Europeans) with a lead variant associated with LDL-C, rs11153594, and the 
rs11153594-C allele associated with increased LDL-C pairs with the rs10872142-C allele. 
Induced pluripotent stem cells homozygous for the rs10872142-C allele showed higher FRK 
expression compared to cells heterozygous (A/C) at rs10872142. Variants detected by 
MPRA screens still require further experimental validation.
Taken together, MPRAs can be useful at narrowing down and identifying GWAS regulatory 
variants. These assays can be especially beneficial if there are numerous candidate 
functional variants at an association signal, because they enable a large number of variants to 
be screened in an experiment. MPRAs require a greater cost per experiment but cost 
substantially less per variant than assays of individual variants. However, limitations to 
MPRAs remain, as study designs may not successfully capture all potential regulatory 
variants, leading to false negatives, and the assays still remove putative regulatory regions 
from their natural chromatin conformation and cellular context, which may be necessary to 
observe functional consequences. MPRAs have a larger computational requirement to design 
reagents and to analyze high-throughput sequencing reads compared to individual 
transcriptional reporter assays. Additionally, while MPRAs can help detect regulatory 
variants that affect transcriptional activity, they would not identify variants that affect 
integrated processes such as mRNA splicing.
Genomic editing to characterize regulatory variants and elements
Another exciting method to examine the effect of regulatory elements and variants at GWAS 
loci is genomic editing followed by assays of gene expression and/or gene function (Figure 
1). Genomic editing can be achieved through using clustered regularly interspaced short 
palindromic repeats (CRISPR) technology, guide RNAs, and Cas9 nuclease protein to create 
double-stranded breaks at target DNA sequences [38–40]. The double-stranded breaks can 
be repaired by non-homologous end-joining (NHEJ), which is more error-prone and often 
results in insertions or deletions of the targeted sequence, or by homology-directed repair, 
which repairs the break using template DNA, yet is less efficient [41]. Using the CRISPR-
Cas9 system, one can disrupt or delete a regulatory element or substitute variant allele(s). 
Isolated clones of cells containing heterozygous or homozygous edits, or in some cases, 
pools of edited cells or organisms, can be analyzed to assess the effects on gene expression 
and/or gene function [42,43].
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Genome editing has been used recently to delete regulatory elements at GWAS signals for 
lipid traits and coronary artery disease. At ANGPTL3/DOCK7, a well-established locus that 
alters blood cholesterol and triglyceride levels [44,45], Pashos and colleagues deleted ∼40 
bp spanning candidate regulatory variant rs10889356 in pluripotent stem cell lines. In 
undifferentiated cells, deletion of the putative regulatory element reduced expression of 
DOCK7, and after differentiation into hepatocyte-like cells, deletion-containing cells 
showed both decreased DOCK7 expression and increased ANGPTL3 expression [37]. 
Nonsense mutations in ANGPTL3 have been found in individuals with combined 
hypolipidemia [44]. At an association signal for multiple traits including coronary artery 
disease, Gupta and colleagues deleted ∼90 bp spanning rs9349379 in pluripotent stem cells. 
After differentiation into endothelial and vascular smooth muscle cells, deletion-containing 
cells showed increased expression of EDN1 compared to wild-type cells [46]. Both 
experiments served to validate the target gene and direction of effect of the predicted 
regulatory element.
Editing cells or organisms to create allele substitutions can provide an unambiguous test of a 
variant's effect. Pashos and colleagues replaced the rs10872142-C allele with the 
rs10872142-A allele in an induced pluripotent stem cell line and observed decreased FRK 
expression [37]. Gupta and colleagues performed two steps of genome editing to create stem 
cell lines homozygous for either the rs9349379-A or G allele to further validate the variant 
effect on EDN1 gene and protein levels. The authors found that endothelial cells 
homozygous for the coronary artery disease risk allele rs9349379-G showed higher EDN1 
expression and higher levels of the encoded vasoconstrictor protein, which they hypothesize 
results in the increased disease risk [46].
Overall, genome editing provides a valuable and precise tool to elucidate effects of genetic 
variation on genes. Generating deletions and/or allelic substitutions allows variant or 
element effects to be evaluated in their genomic and cellular context, in contrast to 
approaches that employ transient transfection or transduction of exogenous DNA and 
reporter gene vectors. The ability to create deletions and substitutions allows multiple types 
of variants, including splicing variants, to be examined. Despite the utility of studying 
variant substitutions, the relatively inefficient homology-directed repair pathway still 
presents challenges in evaluating allelic effects of individual or multiple variants.
Conclusions and perspective
The discovery of hundreds of GWAS loci has provided an unparalleled opportunity to better 
understand the molecular basis of complex disease, yet for many loci, the underlying genes 
and mechanisms remain unknown. The many noncoding disease risk variants may not 
necessarily affect expression of the nearest gene, may act on more than one gene, and may 
increase or decrease gene expression. These points highlight the value of functional assays 
to investigate the molecular mechanisms responsible for GWAS associations. Functional 
genomics regulatory annotation data combined with experimental assays, such as 
transcriptional reporter assays in a cellular context and genome editing, can pinpoint 
regulatory regions and/or variants at GWAS signals.
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Recent functional studies have demonstrated the complexity of regulatory variant 
contributions to GWAS loci. Transcriptional reporter assays, especially MPRAs, have 
demonstrated that many variants located in annotated regulatory elements do not exhibit 
effects on transcriptional activity and that variants outside annotated elements can show 
effects on activity [36]. These results suggest that many potential regulatory variants do not 
have functional consequences and/or transcriptional assays may be imperfect. While 
chromatin annotations can be useful in guiding the selection of candidate regulatory variants 
to test in experimental assays, these annotations shouldn't be used exclusively to define 
which variants are regulatory. In addition, while single functional variants have been 
implicated at some loci, MPRAs often detect multiple variants that exhibit significant allelic 
or haplotype differences in transcriptional activity [35,36], and rigorous functional studies 
have demonstrated that more than one variant on the same haplotype can affect gene 
regulation [26,24]. Furthermore, variants on different haplotypes, often detected as different 
association signals, can affect regulation or function of the same or potentially different 
genes.
An important study design consideration for functional assays to characterize GWAS loci is 
cell type. Cell lines are readily available, relatively straight-forward to maintain, and 
proliferate, enabling large-scale and repeatable studies. However, some regulatory elements 
and variants may only act in a specific cell or tissue, or under specific environmental 
conditions or stimuli [28,37,47], neither of which might be apparent from the phenotype or 
expression pattern of candidate genes. Testing candidate regulatory variants in pluripotent 
stem cells that can be differentiated into appropriate cell types is becoming more routine. 
Cell type may also be important for measuring the effects of altered gene expression on 
biological function such as cholesterol synthesis or atherosclerotic plaque formation.
Although we are starting to understand the roles of individual variant and genes at GWAS 
loci, many loci remain poorly understood. Additional and improved high-throughput 
methods are needed to more efficiently screen thorough sets of candidate variants, yet 
screens alone will likely remain insufficient, and rigorous validation of variant and gene 
effects will be required. Due to of the limitations of each individual assay, a combination of 
assays will be especially valuable to provide more lines of evidence and a clearer picture 
into the molecular and biological mechanisms responsible for lipid traits and coronary artery 
disease.
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Figure 1. Recent strategies for identifying regulatory variants and elements using functional 
genomics assays
DNA segments can be cloned into a vector containing a reporter gene, one at a time or in a 
library. Reporter activity is then measured and compared to the reporter activity of a control 
vector or input DNA. These assays can be used to identify variants that show allelic 
differences in transcriptional activity. Candidate regulatory variants and their effect on gene 
expression and function can be further investigated by genomic editing methods. The DNA 
segment containing the candidate regulatory variant(s) can be targeted using CRISPR-Cas9 
methods and a guide RNA to generate double-stranded breaks. Insertions or deletions can be 
generated by non-homologous end joining, or allelic substitutions can be generated by 
homology-directed repair with the addition of a donor DNA template. The effects of these 
edits can be tested by evaluating gene expression levels, protein levels, and biological 
function.
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Figure 2. Chromatin regulatory annotations predict rs10872142 is located within an enhancer
, rs10872142 is strongly linked with LDL-C-associated lead GWAS variant rs11153594 and 
was reported as a regulatory variant associated with FRK gene expression in liver [37]. 
H3K4me1 ChIP-seq peaks are shown for adipose-derived mesenchymal stem cells and 
primary adipose nuclei (top green tracks) from the NIH Epigenomics Roadmap 
Consortium's Human Epigenome Atlas [10]. H3K4me1, H3K4me2, or H3K4me3 represent 
mono-, di- or tri-methylation of lysine 4 of histone H3, and are modifications commonly 
observed in regulatory enhancer or promoter regions [18,19]. ENCODE H3K4me1,2,3 
ChIP-seq, DNase, and FAIRE peaks are shown for HepG2 hepatocellular carcinoma cells 
(purple tracks), and H3K4me1 ChIP-seq and DNase peaks are shown for human adult liver 
and hepatocytes (black tracks) [9]. The DNase and FAIRE peaks represent open, accessible 
chromatin regions devoid of histones, and the peaks corresponding to H3K4me1, H3K4me2 
and H3K4me3 marks on the adjacent histones are commonly observed at regulatory 
enhancer and/or promoter regions. The multiple tracks provide greater evidence that the 
variant is located within a regulatory region.
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Table 1
Acronyms for terms and assays used to study noncoding, regulatory regions
Acronym Full name Description
DNase DNase I hypersensitivity assay used to detect open, accessible chromatin regions
FAIRE Formaldehyde-assisted isolation of regulatory elements assay used to detect open, accessible chromatin regions
ATAC-seq Assay for transposase-accessible chromatin with high-
throughput sequencing
assay used to detect open, accessible chromatin regions
ChIP Chromatin immunoprecipitation assay used to detect protein binding or histone 
modifications
TAD Topologically associated domain term used to describe three-dimensional chromatin 
organization and interacting regions
FIRE Frequently interacting regions term used to describe three-dimensional chromatin 
organization
3C, 4C, 5C, HiC, 
ChIA-PET
Chromosome conformation capture, “ -on-chip,” -carbon 
copy, chromatin interaction analysis by paired-end tag 
sequencing
assays used to detect chromatin contacts, chromatin 
organization
EMSA Electrophoretic mobility shift assay assay used to detect proteins bound to a nucleotide 
sequence
MPRA Massively parallel reporter assay assay used to test candidates for effects on transcriptional 
activity
CRISPR Clustered regularly interspaced short palindromic repeats used typically with Cas9 protein and guide RNAs for 
genomic editing
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